

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 24, 2021**

**Intra-Cellular Therapies, Inc.**

(Exact name of registrant as specified in its charter)

**Commission File Number: 001-36274**

**Delaware**  
(State or other jurisdiction  
of incorporation)

**36-4742850**  
(IRS Employer  
Identification No.)

**430 East 29th Street  
New York, NY 10016**  
(Address of principal executive offices, including zip code)

**(646) 440-9333**  
(Registrant's telephone number, including area code)

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
<b>Common Stock</b>	<b>ITCI</b>	<b>The Nasdaq Global Select Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**ITEM 1.01 Entry into a Material Definitive Agreement.**

On December 24, 2021, Intra-Cellular Therapies, Inc. (the “Company”) entered into the Amendment (the “Amendment”) to the Supply Agreement dated as of January 4, 2017 (the “Supply Agreement”) by and between Siegfried Evionnaz SA (“Siegfried”) and ITI Limited, a wholly-owned subsidiary of the Company, to extend the current term of the Supply Agreement until January 4, 2023.

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached as Exhibit 10.1 to this Current Report on Form 8-K.

**ITEM 9.01 Financial Statements and Exhibits.****(d) Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
10.1	<a href="#">Amendment to Supply Agreement dated as of December 24, 2021 by and between Siegfried Evionnaz SA and ITI Limited</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTRA-CELLULAR THERAPIES, INC.**

By: /s/ Lawrence J. Hinline  
Lawrence J. Hinline  
Senior Vice President of Finance, Chief Financial  
Officer, Treasurer and Assistant Secretary

Date: December 29, 2021

## AMENDMENT

This Amendment (the **Amendment**) is made as of 24. December 2021 (the **Amendment Effective Date**) between

**Siegfried Evionnaz SA**

Route du Simplon 1, 36, 1902 Evionnaz, Switzerland

(Siegfried)

and, on the other hand

**ITI Limited**

Clarendon House, 2 Church Street, PO Box HM 666, Hamilton, HM CX, Bermuda

(ITI)

to the Supply Agreement between Siegfried and ITI dated January 4, 2017 (the **Agreement**)

**The Parties hereby agree as follows:**

1. A new section 10.5 shall be added to the end of Section of the Agreement:

*“Notwithstanding the foregoing, after the expiry of the initial term set forth in Section 10.1 of the agreement, the Parties agree to mutually extend the term of this Agreement for an additional period of one (1) year. This Agreement shall therefore automatically expire on January 4, 2023 and shall not automatically be renewed.”*

2. All other terms and conditions of the Agreement shall remain unchanged and in full force and effect.
3. This Amendment shall be governed by and construed in accordance with the laws set forth in the Agreement and shall be signed electronically via DocuSign.

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their respective authorized representatives, effective as of the Amendment Effective Date.

**Siegfried Evionnaz SA**

---

/s/ Signer Marcel

Name: Signer Marcel  
Title: Site Manager  
Date: December 24, 2021

---

/s/ Luca Parlanti

Name: Luca Parlanti  
Title: Head of Exclusive Sales DS  
Date: December 24, 2021

**ITI Limited**

---

/s/ Allen Fienberg

Name: Allen Fienberg  
Title: VP Business Development  
Date: December 23, 2021

---

/s/ Larry Hinline

Name: Larry Hinline  
Title: CFO  
Date: December 23, 2021